Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07446855 (PARTHENON) for Solid Tumours is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Back to Search
AstraZenecaStudy of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours (PARTHENON) Phase 1, Phase 2 180
Clinical Trial NCT07446855 (PARTHENON) is designed to study Treatment for Solid Tumours. It is a Phase 1 Phase 2 interventional study that is recruiting, having started on March 17, 2026, with plans to enroll 180 participants. Led by AstraZeneca, it is expected to complete by March 29, 2030. The latest data from ClinicalTrials.gov was last updated on March 27, 2026.
Brief Summary
The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies.
Detailed Description
The study consists of individual modules each evaluating the safety and tolerability of AZD4956 dosed as monotherapy, or with a specific combination partner. There are following 2 modules -
- Module 1: AZD4956 monotherapy
- Module 2: AZD4956 in combination with saruparib
Each module may further contain 2 parts-
- Part A (dose escalation/dose finding): To determine the safety, tolerability, PK, PD, and preliminar...
Official Title
A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours
Conditions
Solid TumoursOther Study IDs
- PARTHENON
- D8570C00001
- 2025-524171-22-00 (EU Study (CTIS) Number)
NCT ID Number
Start Date (Actual)
2026-03-17
Last Update Posted
2026-03-27
Completion Date (Estimated)
2030-03-29
Enrollment (Estimated)
180
Study Type
Interventional
PHASE
Phase 1
Phase 2
Phase 2
Status
Recruiting
Keywords
Advanced/metastatic homologous recombination repair defective solid tumours
Poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi)
Pharmacokinetics
Pharmacodynamics
Poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi)
Pharmacokinetics
Pharmacodynamics
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Sequential
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalModule 1 Part A: AZD4956 monotherapy (Dose escalation) Participants will receive AZD4956 as monotherapy at ascending dose levels. | AZD4956 AZD4956 will be administered orally. |
ExperimentalModule 2 Part A: AZD4956 + saruparib (Dose escalation) Participants will receive AZD4956 at ascending dose levels in combination with saruparib. | AZD4956 AZD4956 will be administered orally. Saruparib Saruparib will be administered orally. |
ExperimentalModule 2 Part A Optional PD backfill cohort: AZD4956 + saruparib Participants will receive AZD4956 in combination with saruparib. | AZD4956 AZD4956 will be administered orally. Saruparib Saruparib will be administered orally. |
ExperimentalModule 2 Part A Optional PD backfill cohort: Saruparib monotherapy Participants will receive saruparib monotherapy. | Saruparib Saruparib will be administered orally. |
ExperimentalModule 2 Part A Optional non-PD backfill cohort: AZD4956 + saruparib Participants with metastatic castrate resistant prostate cancer (mCRPC) will receive AZD4956 in combination with saruparib. | AZD4956 AZD4956 will be administered orally. Saruparib Saruparib will be administered orally. |
ExperimentalModule 2 Part B: AZD4956 + saruparib (Dose expansion) Participants will receive AZD4956 in combination with saruparib. | AZD4956 AZD4956 will be administered orally. Saruparib Saruparib will be administered orally. |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Parts A and B: Number of participants with adverse events (AEs) and serious adverse events (SAEs) | To assess the safety and tolerability of AZD4956 monotherapy and in combination with anti-cancer agent(s). | From Screening (Day -28) to follow-up (up to 3.5 years) |
Part B: Progression free survival (PFS) | PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participants withdraw from study treatment or receive another anti-cancer therapy prior to progression. | Up to 3.5 years |
Part A - Number of participants with dose-limiting toxicities (DLTs) | To assess the safety and tolerability of AZD4956 monotherapy and in combination with anti-cancer agent(s). | Up to 28 days |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Objective response (OR) | OR is defined as if a participant achieves a best overall response (BOR) of confirmed complete response (CR) or partial response (PR), as assessed by the investigator, according to response evaluation criteria in solid tumours (RECIST) v1.1 criterion. | Up to 3.5 years |
Duration of response (DoR) | DoR is defined as the time from the date of first documented OR assessed by RECIST v1.1, in the absence of progression on bone scan assessed by prostate cancer working group 3 (PCWG3), until the date of documented disease progression or death in the absence of disease progression. | Up to 3.5 years |
Best Overall Response (BOR) | To assess the preliminary anti-tumour activity of AZD4956 monotherapy and in combination with anti-cancer agent(s). | Up to 3.5 years |
Time to response (TTR) | TTR is defined as the time from the date of first dose of study intervention until the date of first documented OR assessed by RECIST v1.1, in the absence of progression on bone scan assessed by PCWG3, which is subsequently confirmed. | Up to 3.5 years |
Disease control (DC) | DC is defined as if a participant has achieved a best OR of confirmed CR or PR or SD as BOR assessed by RECIST v1.1, in the absence of progression on bone scan assessed by PCWG3. | Up to 3.5 years |
Clinical benefit rate (CBR) | CBR is defined as the percentage of advanced cancer participants who achieve CR, PR, or at least 16 weeks/24 weeks of stable disease, assessed by RECIST v1.1, in the absence of progression on bone scan assessed by PCWG3, as a result of therapy. | Up to 3.5 years |
Part A: Progression free survival (PFS) | PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participants withdraw from study treatment or receive another anti-cancer therapy prior to progression. | Up to 3.5 years |
Percentage change from baseline in tumour size | The best percentage change from baseline in target lesion (TL) tumour size is the largest decrease (or smallest increase) from baseline for a participant, using RECIST v1.1 assessments. | Up to 3.5 years |
Number of participants with cancer antigen 125 (CA125) response (for ovarian cancer participants) | CA125 response is defined as if at least a 50% reduction in CA125 levels from a pre-treatment sample. | From baseline up to 3.5 years |
Radiological progression free survival (rPFS) (for prostate cancer participants) | PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participants withdraw from study treatment or receive another anti-cancer therapy prior to progression. | Up to 3.5 years |
Change from baseline in prostate specific antigen 50 (PSA50) response rate (for prostate cancer participants) | PSA50 response is defined as if a ≥ 50% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later has been achieved. | From baseline up to 3.5 years |
Change from baseline in PSA90 response rate (for prostate cancer participants) | PSA90 response is defined as if a ≥ 90% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later has been achieved. | From baseline up to 3.5 years |
Change from baseline in PSA undetectable rate | Undetectable PSA is defined as a measurement of \< 0.2 ng/mL. | At 3, 6 and 9 months |
Time to PSA50/90 response (for prostate cancer participants) | Time to PSA50/90 response is defined as the time from the date of first dose of study intervention until the date of first documented PSA response (≥ 50%/90% decrease in PSA from baseline) that is confirmed by a second consecutive PSA assessment at least 3 weeks later. | Up to 3.5 years |
Time to PSA progression (for prostate cancer participants) | Time to PSA progression is defined as the time from date of first dose of study intervention until the date of first documented PSA progression or the last PSA result in the absence of progression. | Up to 3.5 years |
PSA PFS at 6 months (PSA-6) | PSA progression is defined as an increase in PSA of ≥ 25% from the nadir and an absolute increase of at least 2 ng/mL above nadir beyond 12 weeks. To assess the preliminary anti-tumour activity of AZD4956 monotherapy and in combination with anti-cancer. agent(s) | At 6 months |
Area under the concentration-time curve (AUC) | To characterise the pharmacokinetics (PK) of AZD4956 when given orally as monotherapy and in combination with anti-cancer agent(s). | From date of first dose of study intervention up to 59 days after first dose |
Maximum concentration (Cmax) | To characterise the pharmacokinetics (PK) of AZD4956 when given orally as monotherapy and in combination with anti-cancer agent(s). | From date of first dose of study intervention up to 59 days after first dose |
Time to maximum concentration (Tmax) | To characterise the pharmacokinetics (PK) of AZD4956 when given orally as monotherapy and in combination with anti-cancer agent(s). | From date of first dose of study intervention up to 59 days after first dose |
Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 (fe(t1-t2)) | To characterise the pharmacokinetics (PK) of AZD4956 when given orally as monotherapy and in combination with anti-cancer agent(s). | From date of first dose of study intervention up to 16 days after first dose |
Renal clearance (CLR) | To characterise the pharmacokinetics (PK) of AZD4956 when given orally as monotherapy and in combination with anti-cancer agent(s). | From date of first dose of study intervention up to 16 days after first dose |
Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 (Ae(t1-t2)) | To characterise the pharmacokinetics (PK) of AZD4956 when given orally as monotherapy and in combination with anti-cancer agent(s). | From date of first dose of study intervention up to 16 days after first dose |
Change in amount of KRAB-associated protein-1 phosphorylated on serine 824 [pKAP1 (Ser824)] biomarker in tumour cells at baseline and during treatment | To evaluate PD of AZD4956 in tumour cells when given orally as monotherapy and in combination with anti-cancer agent(s). | From Baseline up to 3.5 years |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Documented locally advanced or metastatic solid tumour malignancy.
- Eastern cooperative oncology group (ECOG) performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to screening and first day of dosing.
- Minimum life expectancy ≥ 12 weeks.
- Adequate organ and marrow function.
- Female participants must not breastfeed and must not donate or retrieve ova for their own use from screening to approximately 6 months after the last dose of study intervention.
Module 1 Inclusion Criteria:
- Demonstrated evidence of disease progression.
- Participants must have advanced or metastatic solid tumours.
- Participants may have received up to one prior line of therapy with a poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi)-based regimen (either as a treatment or as maintenance).
Module 2 Inclusion Criteria:
Part A (AZD4956 in Combination with Saruparib Dose Escalation) and Part A-PD (PD Backfill Cohorts):
Participants must have one of the following conditions-
- Histologically or cytologically confirmed carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or somatic mutation.
- Histologically or cytologically confirmed advanced ovarian, fallopian tube, or primary peritoneal cancer.
- Histologically or cytologically confirmed adenocarcinoma of the prostate and advanced/metastatic castrate resistant prostate cancer (CRPC).
- Histologically or cytologically confirmed advanced/metastatic pancreatic cancer.
Participants must have evaluable disease.
Participants in PD backfill cohorts must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance).
Part A (PD Backfill Cohorts) - Participants Undergoing Paired Biopsies:
- Participants must have a tumour suitable for biopsy.
Part A-Non-PD (Non-PD Backfill Cohorts) and Part B (Dose Expansion Cohorts):
- Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate and advanced/metastatic CRPC.
- Participants must have documented metastatic disease by clear evidence of ≥ 1 bone lesion (defined as one lesion with positive uptake on bone scan) and/or ≥ 1 soft tissue lesion (measurable or non-measurable).
- Participants must have received the prior approved systemic therapies for metastatic prostate cancer.
- Participants must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance).
- Any significant laboratory finding or any severe and uncontrolled medical condition.
- Participants with any known predisposition to bleeding.
- Spinal cord compression or symptomatic and unstable brain metastases or leptomeningeal disease.
- Allogenic organ transplantation.
- Known to have active infection, including hepatitis B virus (HBV) or hepatitis C virus (HCV).
- Known history of infection with human immunodeficiency virus (HIV).
- Active gastrointestinal disease or other condition that will interfere significantly with the swallowing, absorption, distribution, metabolism or excretion of oral therapy.
- Participants with history of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML.
- Participants with a known hypersensitivity to the investigational product(s) or any of the excipients of the product(s).
- Previous dosing with AZD4956.
AstraZenecaStudy Central Contact
Contact: AstraZeneca Clinical Study Information Center, 1-877-240-9479, [email protected]
13 Study Locations in 6 Countries
Research Site, London, SE1 9RT, United Kingdom
Not yet recruiting
Research Site, Sutton, SM25PT, United Kingdom
Not yet recruiting
New York
Research Site, New York, New York, 10065, United States
Not yet recruiting
Rhode Island
Research Site, Providence, Rhode Island, 02903, United States
Not yet recruiting
Texas
Research Site, Houston, Texas, 77030, United States
Not yet recruiting
Virginia
Research Site, Fairfax, Virginia, 22031, United States
Recruiting
Research Site, Melbourne, 3000, Australia
Not yet recruiting
Research Site, Chūōku, 104-0045, Japan
Not yet recruiting
Research Site, Kashiwa, 277-8577, Japan
Not yet recruiting
Research Site, Seoul, 03080, South Korea
Not yet recruiting
Research Site, Seoul, 120-752, South Korea
Not yet recruiting
Research Site, Barcelona, 8035, Spain
Not yet recruiting
Research Site, Pozuelo de Alarcón, 28223, Spain
Not yet recruiting